Keros Therapeutics (KROS) Assets Average (2020 - 2026)
Keros Therapeutics' (KROS) quarterly Assets Average came in at $540.4 million in Q4 2025, down 9.57% YoY from $597.6 million in Q4 2024, and down 27.94% on a QoQ basis from $750.0 million in Q3 2025.
Keros Therapeutics (KROS) Assets Average (2020 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of Assets Average data on file, last reported at $540.4 million in Q4 2025.
- Quarterly Assets Average fell 9.57% year-over-year to $540.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $540.4 million (down 9.57% YoY) and the FY2025 annual result came in at $477.0 million, down 3.25% from the prior year.
- Assets Average eased to $540.4 million in Q4 2025, from $750.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $770.9 million in Q2 2025 to a low of $230.9 million in Q2 2022.
- A 5-year average of $408.4 million and a median of $346.9 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average soared 636.82% — and 2025, when it slipped 9.57%.
- Tracing KROS's Assets Average over 5 years: stood at $242.6 million in 2021, then rose by 15.28% to $279.7 million in 2022, then rose by 24.48% to $348.1 million in 2023, then jumped by 71.65% to $597.6 million in 2024, then retreated by 9.57% to $540.4 million in 2025.
- The last three Assets Average figures came in at $540.4 million (Q4 2025), $750.0 million (Q3 2025), and $770.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 312.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 312.81 Mn |
| Dec 31, 2025 | 540.40 Mn |
| Sep 30, 2025 | 749.97 Mn |
| Jun 30, 2025 | 770.86 Mn |
| Mar 31, 2025 | 700.22 Mn |
| Dec 31, 2024 | 597.58 Mn |
| Sep 30, 2024 | 517.15 Mn |
| Jun 30, 2024 | 470.42 Mn |
| Mar 31, 2024 | 427.92 Mn |
| Dec 31, 2023 | 348.14 Mn |
| Sep 30, 2023 | 341.28 Mn |
| Jun 30, 2023 | 370.37 Mn |
| Mar 31, 2023 | 345.61 Mn |
| Dec 31, 2022 | 279.67 Mn |
| Sep 30, 2022 | 239.61 Mn |
| Jun 30, 2022 | 230.90 Mn |
| Mar 31, 2022 | 245.20 Mn |
| Dec 31, 2021 | 242.61 Mn |
| Sep 30, 2021 | 236.71 Mn |
| Jun 30, 2021 | 250.60 Mn |